Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Black Diamond Therapeutics (BDTX) Interest & Investment Income (2019 - 2025)

Black Diamond Therapeutics (BDTX) has disclosed Interest & Investment Income for 3 consecutive years, with $588000.0 as the latest value for Q4 2021.

  • For the quarter ending Q4 2021, Interest & Investment Income fell 53.11% year-over-year to $588000.0, compared with a TTM value of $3.5 million through Dec 2021, down 14.28%, and an annual FY2024 reading of $2.2 million, up 13.41% over the prior year.
  • Interest & Investment Income was $588000.0 for Q4 2021 at Black Diamond Therapeutics, down from $776000.0 in the prior quarter.
  • Across five years, Interest & Investment Income topped out at $1.3 million in Q4 2020 and bottomed at $1000.0 in Q3 2019.
  • Average Interest & Investment Income over 3 years is $663833.3, with a median of $760000.0 recorded in 2020.
  • The sharpest move saw Interest & Investment Income surged 116100.0% in 2020, then plummeted 53.11% in 2021.
  • Year by year, Interest & Investment Income stood at $440000.0 in 2019, then soared by 185.0% to $1.3 million in 2020, then tumbled by 53.11% to $588000.0 in 2021.
  • Business Quant data shows Interest & Investment Income for BDTX at $588000.0 in Q4 2021, $776000.0 in Q3 2021, and $948000.0 in Q2 2021.